Invitro International
InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivi… Read more
Invitro International - Asset Resilience Ratio
Invitro International (IVRO) has an Asset Resilience Ratio of 52.76% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Invitro International's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Invitro International's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $834.17K | 52.76% |
| Total Liquid Assets | $834.17K | 52.76% |
Asset Resilience Insights
- Very High Liquidity: Invitro International maintains exceptional liquid asset reserves at 52.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Invitro International Industry Peers by Asset Resilience Ratio
Compare Invitro International's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Invitro International (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Invitro International.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-09-30 | 53.16% | $815.53K | $1.53 Million | +5.06pp |
| 2021-09-30 | 48.10% | $784.97K | $1.63 Million | -2.94pp |
| 2020-09-30 | 51.05% | $785.61K | $1.54 Million | -2.44pp |
| 2019-09-30 | 53.48% | $738.00K | $1.38 Million | +16.18pp |
| 2017-09-30 | 37.31% | $433.02K | $1.16 Million | -- |